Learn about the increased pressure in the portal vein, its causes like cirrhosis, and resulting complications such as ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended ...

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), said “In the U.S. approximately 5 million adults are ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

20.0%). These results further support the potential of the 2 mg dose in preventing varices in MASH cirrhosis patients with portal hypertension. I believe the results warrant further clinical ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Researchers provide a conceptual overview of liver vasomics, including the classification of vascular phenotypes in the liver ...

Medically reviewed by Jay N. Yepuri, MD Metabolic dysfunction-associated fatty liver disease (MAFLD) occurs when excess fat builds up in the liver. MAFLD can progress to metabolic ...

Chronic hepatitis B (CHB) is currently estimated to affect over 250 million people worldwide, and tenofovir disoproxil ...